Latest Articles

Publication Date
Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study.

Background/Objectives: Current studies on adverse events related to the COVID-19 vaccine have predominantly focused on severe, life-threatening side effects. However, numerous less severe but common adverse events (AEs) remain underreported …

Published: March 6, 2025, midnight
Traumatic Experiences and Adverse Events Contribute to the Endometriosis Pathogenesis - Yale School of Medicine

Traumatic Experiences and Adverse Events Contribute to the Endometriosis Pathogenesis Yale School of Medicine

Published: Feb. 5, 2025, 8:51 p.m.
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
Ultrasound and single-port laparoscopic-guided microwave ablation of abdominal wall endometriosis lesions: A single-center observational study.

Raising the temperature of abdominal wall endometriosis lesions contributes to an effective ablation; however, providing sufficient protection to the surrounding tissues remains a challenge. In this study, we aimed to …

Published: Jan. 22, 2025, midnight
Percutaneous Cryoablation Therapy for Abdominal wall Endometriosis: a Systematic Review and Meta-analysis.

Abdominal wall endometriosis consists of endometrial tissue between the peritoneum and the abdominal wall. The established treatment involves amenorrheic drugs-not always successful and tolerated-or invasive surgery. In this scenario, minimally …

Published: Jan. 16, 2025, midnight
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA …

Published: Dec. 11, 2024, midnight
Endometriosis and risk factors in pregnancy, labor and delivery: a case-control study.

It is a common thought that endometriosis and its related pain symptoms could improve during pregnancy. However, endometriosis was shown to affect the regular development of pregnancy and delivery outcomes. …

Published: Nov. 8, 2024, midnight
Self-Cross-Linked Hyaluronic Acid Gel for Adhesion Prophylaxis in Laparoscopic Deep Endometriosis Removal: Safety Report of a Prospective Pilot Study.

Background/Objectives: Surgical removal of deep endometriosis lesions is an established method of reducing patient symptoms, but it often results in iatrogenic adhesions that lead to further problems. This pilot study …

Published: Oct. 21, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!